| Abstrakt: |
A recent study conducted at the University of Buenos Aires in Argentina explored the potential use of methylene blue (MB) as a neuroprotective agent in the treatment of glaucoma. Glaucoma is a leading cause of blindness worldwide, often resulting from elevated intraocular pressure and the death of retinal ganglion cells. The study involved Wistar rats that underwent episcleral vein cauterization (EVC) in one eye, while the other eye served as a control. The rats were then treated with either MB or a placebo for seven days. The results showed that MB treatment significantly restored the amplitude and complexity of electroretinography (ERG) parameters, as well as the amplitude of pattern electroretinography (PERG) parameters. Additionally, MB treatment prevented the loss of retinal ganglion cells and inner retina thickness caused by EVC. The researchers concluded that MB could be an effective pharmacological strategy for preventing vision loss in glaucoma patients. [Extracted from the article] |
